As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Mangoceuticals Inc. (NASDAQ:MGRX) is on a mission to rewrite the playbook for men’s performance, health, and vitality. Its pursuit comes at a time when opportunities have become enormous, with patent ...

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they can persuade US regulators their products are legal ...

Counterfeit forms of weight loss and diabetes drugs are endangering consumers, and Oklahoma General Attorney Gentner Drummond wants to take action against what he calls "bad actors" in the ...

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

The trial was sponsored by Novo Nordisk, the pharmaceutical company that manufactures semaglutide under brand names like Ozempic and Rybelsus. While the results are promising, researchers note ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide ... including the first draft, under the direction of the authors; Beverly La Ferla, M.Res., and Helen Marshall, B.A ...

its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals. These results reinforce the company’s commitment to addressing chronic ...

Oral semaglutide (Rybelsus; Novo Nordisk) taken once daily cut the risk of cardiovascular mortality, nonfatal MI, or nonfatal stroke in the trial by 14% after a mean follow-up of 47.5 months, a ...